[ad_1]
Lyon, France, June 15, 2021 (GLOBE NEWSWIRE) – ADOCIA (Paris Euronext: FR0011184241 – ADOC) is a clinical-stage biopharmaceutical company that specializes in the development of innovative protein and peptide formulations. It announced today that Adocia will carry out Oral report on dual hormone therapy M1Pram (ADO09) 81Yingshi American Diabetes Association Scientific Conference It will be held as a virtual event from June 25th to 29th, 2021.
The main results of this active research are in a Press release Distributed on September 15, 2020.
In this oral report, Gregory Meiffren, Director of Clinical Development of Adocia, will introduce the study and its main results.
| Appointment time: Sunday, June 27 (East)-4:00 PM-4:15 PM title: 197-OR-ADO09, a combination of insulin A21G and Pramlintide (Pram), can improve blood sugar control and reduce weight in patients with T1D speaker: Dr. Gregory Mevern period: 15 minutes ADA plan |
Adocia is currently studying M1Pram in the second phase and is expected to obtain results in the second quarter of 2022.
About the American Diabetes Association Scientific Conference
This Scientific Conference of the American Diabetes Association Provide exclusive opportunities for researchers and healthcare professionals from all over the world to share ideas and knowledge about the latest developments in diabetes research, treatment and care. Participants will have the opportunity to obtain more than 3,000 original research reports, participate in thought-provoking lectures with leading diabetes experts, and expand their professional network.
About Adosia
Adosia It is a clinical stage biotechnology company that specializes in the development of innovative formulations of therapeutic proteins and peptides for the treatment of diabetes, obesity and metabolic diseases. In the field of diabetes, Adocia’s injection therapy product portfolio is one of the largest and most differentiated products in the industry, with five clinical stage products and a variety of preclinical products. Proprietary BioChaperone® The technology platform aims to improve the effectiveness and/or safety of therapeutic proteins while making it easier for patients to use. Adocia customized BioChaperone® Every protein used for a given application.
Adocia’s clinical pipeline includes four new insulin preparations for diabetic meal treatment: two ultra-rapid insulin analogue insulin lispro preparations (BioChaperone® Lispro U100 and U200), a combination of basal insulin glargine and fast-acting insulin lispro (BioChaperone® Combo) and a combination of dietary insulin and the amylin analogue Pramlintide M1Pram. The clinical pipeline also includes human glucagon (BioChaperone® Glucagon) is used to treat hypoglycemia.
Adocia’s preclinical pipeline for diabetes treatment includes a dual hormone combination: fast-acting insulin analogues and pramlintide (BioChaperone® Lispro stroller and BioChaperone® Aspart Pram), and the combination of insulin glargine and GLP-1 receptor agonist (BioChaperone® Glycine Liraglutide).
Adocia recently added a cell therapy program that focuses on the development of hydrogel scaffolds for patients with type 1 diabetes. The first patent application to support the plan has been submitted.
Adocia’s preclinical pipeline for the treatment of obesity includes two dual hormone products: a combination of glucagon and exenatide (BioChaperone® Glucagon Exenatide) and the combination of Pramlintide and Exenatide (PramExe).
Contact Adosia
Disclaimer
| This press release contains certain forward-looking statements about Adocia and its business. Such forward-looking statements are based on assumptions that Adocia believes are reasonable.However, there is no guarantee that the estimates contained in such forward-looking statements will be verified. These estimates are subject to a variety of risks, including the risks specified in the “Risk Factors” section of the general registration documents submitted to the French Authority April 20, 2021 (a copy is available at www.adocia.com) And economic development | Conditional financial markets and markets operated by Adocia. The forward-looking statements contained in this press release are also subject to risks that Adocia does not yet know about or that Adocia currently does not consider to be significant risks. The occurrence of all or part of these risks may cause Adocia’s actual results, financial condition, performance or achievements to be materially different from such forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or solicit the purchase of Adocia stock in any jurisdiction. |
[ad_2]
Source link
